$COLL News

Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks

Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026

Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses

Collegium Pharmaceutical And Grünenthal Enter Settlement Agreement On Oct 15, 2026; Terminates Grünenthal License And Consent Agreement For Territory Effective Oct 15, 2026; Co. To Pay Grünenthal $17M In Settlement

COLL vs. DSNKY: Which Stock Is the Better Value Option?

Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut

Does Collegium Pharmaceutical (COLL) Have the Potential to Rally 111.39% as Wall Street Analysts Expect?

Collegium Pharmaceutical Outlook Supported by ADHD Trends, Low Generic Drug Risk, Oppenheimer Says

Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life

Collegium Pharmaceutical Reports Q2 2026 Results: Full Earnings Call Transcript

Oppenheimer Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $50

Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Truist Securities Maintains Buy on Collegium Pharmaceutical, Lowers Price Target to $49

Leerink Partners Initiates Coverage On Collegium Pharmaceutical with Outperform Rating, Announces Price Target of $45

Collegium to Participate in Upcoming Investor Conferences

Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $48

5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call

Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript

Collegium Announces $50 Million Accelerated Share Repurchase Program

COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance